J&J inks in­dus­try's lat­est bolt-on buy­out with $6.5B deal to ac­quire Mo­men­ta, beef­ing up its au­toim­mune pipeline

J&J has struck a deal to buy out Mo­men­ta $MN­TA for $6.5 bil­lion, build­ing up the au­toim­mune sec­tion of the phar­ma gi­ant’s pipeline and adding a prime late-stage drug can­di­date to the mix.

Ear­ly Wednes­day J&J put out word that it is pay­ing $52.50 a share to bag the com­pa­ny. The deal nets out at $6.1 bil­lion once you fac­tor in cash on hand at the biotech.

The prize for J&J is nipocal­imab (M281), which the com­pa­ny de­scribes as a “clin­i­cal­ly val­i­dat­ed, po­ten­tial­ly best-in-class an­ti-FcRn an­ti­body” with po­ten­tial in a range of dis­eases like ma­ter­nal-fe­tal dis­or­ders, neu­ro-in­flam­ma­to­ry dis­or­ders, rheuma­tol­ogy, der­ma­tol­ogy and au­toim­mune hema­tol­ogy. That qual­i­fies as a pipeline in a prod­uct, a key theme these days in M&A.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER